These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14529687)

  • 1. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
    Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
    Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
    Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
    Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ; Jin CJ; Rha SY; Chung HC
    Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
    Katsumi Y; Kuwahara Y; Tamura S; Kikuchi K; Otabe O; Tsuchiya K; Iehara T; Kuroda H; Hosoi H; Sugimoto T
    Clin Cancer Res; 2008 Feb; 14(4):1192-9. PubMed ID: 18281554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
    Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
    Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of HER-2 in ovarian carcinomas.
    Hellström I; Goodman G; Pullman J; Yang Y; Hellström KE
    Cancer Res; 2001 Mar; 61(6):2420-3. PubMed ID: 11289108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
    Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
    Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.